A Prospective Multicenter Assessment of the Accuracy and Safety of the Yuwell CT3 Real-Time Continuous Glucose Monitoring System in Patients With Diabetes Over 14 Days.
This 14-day multicenter study assessed CT3 CGM accuracy and safety in 71 adults with diabetes. Key results: overall MARD 9.1% (median 7.1%), 82.4%-98.2% met %15/15-%30/30 criteria, 99.7% values in CEG zones A/B. CT3 showed strong performance, suitable for reliable 14-day wear.